Therapeutic Focus
Therapeutic Focus

Cardiovascular diseases are the leading cause of death globally, and high levels of LDL-C, or bad cholesterol, are the most readily modifiable risk factor in developing cardiovascular disease.

Read More
Innovative Science
Innovative Science

Small interfering RNA (siRNA) therapies harness a natural pathway to target the root causes of diseases and maintain their efficacy over a prolonged duration of time.

Read More
Clinical Development
Clinical Development

We’re focused on an investigational therapy being evaluated for its ability to produce clinically meaningful reductions in LDL-C, or bad cholesterol. We expect top-line data in Q3 2019.

Read More

The Medicines Company

The Medicines Company is a biopharmaceutical company whose purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C, or bad cholesterol. Our team is focused on transformational solutions that address the daily challenges which patients, physicians and payers confront in cardiovascular care.
Learn More

Latest Tweets @MDCONews

  • The Medicines Company @MDCONews

    In addition to checking LDL-C levels and changing diet & lifestyle, what is the third "C" of successful #cholesterol management?

  • The Medicines Company @MDCONews

    $MDCO is proud to showcase our participation in #AHA19 Scientific Sessions in Philadelphia from November 16-18, including presenting data from the Phase 3 ORION-9 and ORION-10 clinical studies. Learn more https://t.co/F0AAUUk8mg

More

Investors & Media

The Medicines Company has a proud tradition of leadership and a strong commitment to patients with cardiovascular disease. Our organization is focused on delivering great value to patients, physicians and shareholders through a potentially transformative therapy to lower LDL-C, or bad cholesterol.
Learn More

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com